Patents by Inventor Marc Schwerdel

Marc Schwerdel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugates and processes for their preparation and their use for transporting molecules across biological membranes
    Patent number: 8420396
    Abstract: The present invention provides conjugates, processes for their preparation, and the use of these conjugates for transporting low-molecular-weight compounds and macromolecules across biological membranes, in particular for transporting molecules into cells. The present invention also provides pharmaceutical compositions, diagnostic aids, and test kits in which these conjugates are present or used.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: April 16, 2013
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Eugene Uhlmann, Beate Greiner, Eberhard Unger, Gislinde Gothe, Marc Schwerdel
  • CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES
    Publication number: 20080071069
    Abstract: The present invention provides conjugates, processes for their preparation, and the use of these conjugates for transporting low-molecular-weight compounds and macromolecules across biological membranes, in particular for transporting molecules into cells. The present invention also provides pharmaceutical compositions, diagnostic aids, and test kits in which these conjugates are present or used.
    Type: Application
    Filed: January 11, 2007
    Publication date: March 20, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Eugen Uhlmann, Beate Greiner, Eberhard Unger, Gislinde Gothe, Marc Schwerdel
  • Oligonucleotides for the inhibition of human eg5 expression
    Patent number: 6472521
    Abstract: The present invention relates to an oligonucleotide or a derivative thereof which has a sequence that corresponds to a particular fragment of a nucleic acid sequence which encodes human eg5 or a mutant form thereof; the invention further relates to a method of making the oligonucleotide and the use thereof.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: October 29, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Beate Greiner, Eberhard Unger, Gislinde Gothe, Marc Schwerdel